Visit https://www.peervoice.com/QTK860 to view the entire programme with slides. After completing “New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.